Welcome to our dedicated page for TRANSLATE BIO news (Ticker: TBIO), a resource for investors and traders seeking the latest updates and insights on TRANSLATE BIO stock.
Translate Bio (TBIO) delivers cutting-edge synthetic biology solutions through automated DNA/mRNA synthesis platforms. This news hub provides investors and researchers with essential updates on the company’s scientific milestones and strategic developments.
Access official press releases covering product innovations, financial results, and research partnerships. Our curated collection ensures you stay informed about Gibson SOLA platform advancements, BioXp system integrations, and key collaborations driving precision medicine breakthroughs.
Discover updates across critical categories including clinical trial progress, technology licensing agreements, and operational achievements. All content is sourced directly from verified corporate communications to maintain accuracy and compliance.
Bookmark this page for streamlined access to Translate Bio’s latest developments in genetic synthesis technology. Regularly updated to serve as your primary resource for monitoring TBIO’s role in advancing high-throughput biomedical research.
Telesis Bio has secured up to $21 million in financing through a convertible preferred stock purchase agreement, led by Novalis LifeSciences and Northpond Ventures. The funding includes an initial tranche of approximately $17 million ($8 million cash infusion and $9 million debt conversion) and a potential second tranche of $4 million by March 6, 2026.
The company's newly launched Gibson SOLA™ technology enables overnight DNA and mRNA synthesis using standard automated liquid handling equipment. This platform allows researchers to maintain control of their nucleic acid supply chain, protect IP, and retain valuable data for AI drug discovery models. The technology supports the synthesis of complex constructs necessary for biologics, vaccine, and cell therapy research and development.
The financing provides Telesis Bio with a debt-free balance sheet and sufficient capital to achieve cash-flow breakeven while supporting existing customers and expanding adoption of their next-generation platform.
Telesis Bio and Beckman Coulter Life Sciences have announced a collaboration to revolutionize DNA and mRNA synthesis. The partnership aims to create efficient and scalable biofoundries, delivering solutions for sustainable and rapid on-premise synthesis of DNA. This innovative approach combines Telesis Bio's Gibson SOLA enzymatic reagent platform with Beckman Coulter Life Sciences' automation expertise.
The collaboration integrates Telesis Bio's Gibson SOLA Enzymatic Synthesis technology with the new Biomek Echo One System from Beckman Coulter Life Sciences. This integration ensures rapid, reliable, and highly scalable production of extremely high-fidelity DNA, empowering researchers to achieve greater productivity and innovation in various discovery applications.
The partnership aims to establish local and on-premise DNA foundries that function as digital-to-biologic converters, delivering DNA or mRNA as fast as overnight. This collaboration is expected to set a new standard for on-premises biofoundries and drive forward the next generation of therapeutic and diagnostic advancements.
Telesis Bio Inc. (NASDAQ: TBIO) has announced its decision to voluntarily delist its common stock from the Nasdaq Global Select Market. The company plans to file a Form 25 with the SEC on or about September 20, 2024, with the last trading day expected to be around September 30, 2024. This decision comes after Telesis received notifications from Nasdaq regarding non-compliance with the minimum stockholder's equity requirement and the minimum Market Value of Publicly Held Shares (MVPHS) requirement.
Telesis believes it will be unable to regain compliance with these requirements. Following the delisting, the company's common stock is expected to be quoted on an OTC market, although there is no guarantee of continued trading. Telesis will remain subject to reporting obligations under the Exchange Act.
Telesis Bio Inc. (NASDAQ: TBIO) reported its Q2 and H1 2024 financial results. Key highlights include:
1. Revenue decreased to $1.6 million in Q2 2024 from $7.0 million in Q2 2023.
2. Gross margin dropped to -52% in Q2 2024 from 71% in Q2 2023, primarily due to restructuring charges.
3. Operating expenses improved by 14% to $10.7 million in Q2 2024.
4. Net loss increased to $13.2 million ($7.62 per share) in Q2 2024 from $8.4 million ($5.10 per share) in Q2 2023.
5. The company is advancing its Gibson SOLA reagent platform and continuing its Pfizer collaboration.
6. Telesis Bio divested its Eton subsidiary and underwent restructuring to reduce costs.
7. As of June 30, 2024, the company had $10.3 million in cash and equivalents, with $5.3 million in notes payable.
Telesis Bio Inc. reported their financial results for the first quarter of 2024, highlighting their strategic focus on Gibson SOLA and BioXp mRNA solutions. Revenue decreased compared to the same period last year, with operating expenses reduced by 31%. The company continues to make progress with its collaborations and is optimistic about the future.
Telesis Bio Inc. announced a 1-for-18 reverse stock split to comply with Nasdaq's minimum bid price requirement. The split will consolidate every eighteen shares into one, reducing outstanding shares from 30.1 million to 1.7 million. The reverse stock split will not affect preferred stock but will adjust conversion prices and exercise prices of warrants, options, and equity awards.
FAQ
What is the current stock price of TRANSLATE BIO (TBIO)?
What is the market cap of TRANSLATE BIO (TBIO)?
